If approved, HP-3070 would be the first transdermal antipsychotic available in the United States, and would provide a novel, safe, and efficacious treatment delivery system for adult patients with schizophrenia.
Over the course of 52 weeks, a combination of olanzapine and samidorphan was associated with minimal weight gain, tolerable adverse events, and durable antipsychotic effects in patients with schizophrenia.
In addition to improved symptoms, a delayed-release/extended-release methylphenidate was linked with improvements in early morning and late afternoon/evening functional impairment experienced by children with ADHD.
Patients with schizophrenia or a mood disorder who switched antipsychotic treatment had an increased likelihood for relapse, healthcare resource utilization, and extrapyramidal symptoms.
Higher rates of hopelessness, loneliness, anhedonia, social anxiety, and younger age were highly correlated with suicidal ideation in patients with major depressive disorder, based on a review of qualitative data.